Bavarian Nordic updates about vaccine project pipeline In a business update, Danish-based biopharmaceutical company Bavarian Nordic, reported a genuine number of advancements in its vaccine task pipeline no more than 20 mg . Clinical advancement of IMVAMUNE as a secure smallpox vaccine is usually proceeding as planned. Stage III research with IMVAMUNE in healthful subjects are anticipated to become initiated in 2008. Bavarian Nordic received an progress payment of $50 million from the Division of Health insurance and Human Providers as allowed beneath the RFP-3 agreement.
Medical Affairs, Bayer HealthCare Pharmaceuticals.. Bayer completes recruitment of first cohort for BAY 86-6150 Stage II/III research in hemophilia Bayer's BAY 86-6150 has been investigated in a Stage II/III research called TRUST , and the recruitment of the first cohort is complete right now. Recruitment is normally ongoing at sites located around the global world, including in the U.S., where sites will be ready to enroll eligible sufferers. Bayer is focused on finding innovative methods to meet the requirements of individuals with hemophilia, including those suffering from the consequences of inhibitors to clotting element replacement therapies, stated Pamela Cyrus, MD, Vice Head and President, U.S.